A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...

“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...

Add Yahoo as a preferred source to see more of our stories on Google. A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, researchers ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

Brian Holmes is the first man in the UK and the fifth in the world to receive the treatment.

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

New therapies are needed to help prevent the development of this condition. Researchers from the University of Iowa report that males taking three commonly prescribed prostate medications may lower ...

Add Yahoo as a preferred source to see more of our stories on Google. Giles Turner, from Brighton, is one of the men who could benefit from the drug Men with aggressive prostate cancer should be given ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Prostate Cancer Drugs Market was valued at US$ 13.22 billion in 2024 and is projected to reach US$ 28.10 billion by 2033, growing at a CAGR of 8.1 percent ...

Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, phase 3 clinical trial led ...